The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells

Table 1 Sensitivity of the cell lines to CEP-37440

Cell line	Type	Subtype			GI₅₀ (nM)	Reference
		ESR	PgR	ErbB2
FC-IBC02	IBC	Neg	Neg	Neg	91	[10]
KPL4	IBC	Neg	Neg	Post	~900	[41]
SUM190	IBC	Neg	Neg	Post	890	[42]
MDA-IBC03	IBC	Neg	Neg	Post	1860	[43]
SUM149	IBC	Neg	Neg	Neg	>3000	[42]
MCF-12A	Normal-like breast epithelial cells	Neg	Neg	Neg	1516	[44]
MCA-10A	Normal-like breast epithelial cells	Neg	Neg	Neg	1700	[45]
MDA-MB-231	BC (non-IBC)	Neg	Neg	Neg	1930	[46]
MDA-MB-468	BC (non-IBC)	Neg	Neg	Neg	1275	[46]

Inflammatory breast cancer (IBC), breast cancer (BC) non-IBC, and normal-like breast epithelial cell lines were grown in the presence of different concentrations of CEP-37440 (cell proliferation assays). The GI₅₀ indicate the CEP-37440 concentration required to reduce growth rates to 50 % of the maximum rate. The GI₅₀ was calculated for each cell line at t = 144 h of CEP-37440 treatment using sigmoidal dose response curve (variable slope) in GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA)
ESR estrogen receptor, PgR progesterone receptor, ErbB2 epidermal growth factor receptor 2

ISSN: 1465-542X